Please assess the completion status of the following clinical trial:

Trial Title: Trigger-point Blockade in Persistent Pain After Open Groin Hernia Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with persistent pain (\< 6 mo) after open groin hernia repair~* Patients with maximal pain area 3 cm or less from the superficial inguinal ring~* Patients living in the Capital Region of Denmark (Region Hovedstaden) or the Region of Zealand (Region Sjælland)~Exclusion Criteria:~* Known allergy to bupivacaine or other local anesthetics of amide-type~* Declared incapable of making his/hers own affairs~* Does not comprehend Danish in the written or spoken language~* Cognitive impairment to a degree influencing the testing reliability~* Known recurrence of the inguinal hernia~* Other surgical procedures performed in the groin or on the external genitals~* Neuropathy affecting the groin region caused by other conditions, e.g. post-stroke, multiple sclerosis, herniated intervertebral disc~* Abuse of alcohol or drugs~* Unable to cooperate with the sensory examinations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Bupivacaine (Type: EXPERIMENTAL): injection, 25 mg, once, 5 min
- Placebo (Type: PLACEBO_COMPARATOR): injection, 10 ml 0.9% sodium chloride, once, 5 min

Based on this trial design, predict the completion outcome and termination type (if applicable).